Abstract: A mutant TDP-43 protein, having a deletion of a nuclear localization signal sequence in the amino acid sequence of a wild-type TDP-43 protein, and also having any one of the following mutations (a) to (c) or a combination of these mutations: (a) a mutation, in which the 147th and 149th phenylalanines are substituted with leucines, (b) a mutation, in which the 194th phenylalanine is substituted with leucine, and (c) a mutation, in which the 229th and 231st phenylalanines are substituted with leucines.

Abstract: Provided are: a neurodegenerative model animal also exhibiting amyotrophy, the neurodegenerative model animal comprising a nonhuman animal from which both the PNPLA6 and PNPLA7 genes have been deleted; and a method for screening a drug for neurodegenerative disease or a drug for a disease that causes amyotrophy, the screening method involving causing contact of a substance to be examined with said animal or with a biological sample collected from the animal, and using, as an index, an improvement effect with regards to neurodegeneration or amyotrophy of the nonhuman animal or biological sample after contact with the substance to be examined.

Abstract: A heat-resistant alloy contains Y, a content of Ni is a content of Ni is 58.0 mass % or greater, a content of Cr is 20.0 mass % or greater and 23.0 mass % or less, a content of Mo is 8.0 mass % or greater and 10.0 mass % or less, a content of Nb is 3.15 mass % or greater and 4.15 mass % or less, a content of O is 0.002 mass % or greater and 0.1 mass % or less, and a ratio of a content of Y in terms of mass to a content of O in terms of mass is 0.5 or greater and 100 or less.

Abstract: The present invention provides novel and effective cancer immunotherapeutic agents that exhibit therapeutic effects on intractable cancers, particularly cancers for which immune checkpoint inhibitor(s) monotherapy or combined use thereof with other drug(s) is ineffective. Specifically, a cancer therapeutic agent containing an immune checkpoint inhibitor, interleukin-18 (IL-18), and a T cell growth factor (e.g., interleukin-2 (IL-2)) in combination is provided.

Abstract: The object of the present invention is to provide a method for treating or preventing diseases related to mitochondrial function by a substance related to the improvement or decrease of mitochondrial function. The above problem can be solved by the agent for promoting formation of mitochondrial respiratory chain supercomplex, comprising Syk inhibitor as an active ingredient. a composition for maintaining or enhancing muscle strength, comprising the agent for promoting formation of mitochondrial respiratory chain supercomplex, or the pharmaceutical composition for treating or preventing muscle hypofunction disease or mitochondrial hypofunction disease, comprising the agent for promoting formation of mitochondrial respiratory chain supercomplex, of the present invention.

Abstract: A sound source separation program causes a computer to acquire an acoustic signal, convert the acquired acoustic signal from a time region to a frequency region, and perform sound source separation on the acoustic signal converted to the frequency region by performing updating based on elementary row operation on a demixing matrix to iteratively minimize an objective function including a quadratic form of a separation vector and a determinant of the demixing matrix.

Abstract: The object of the present invention is to provide a method for early diagnosing pancreatic cancer and a pharmaceutical composition for treating pancreatic cancer. The object can be solved by a method for assisting a diagnosis of pancreatic cancer, comprising the steps of: (1) bringing a sample derived from a subject suspected of having pancreatic cancer into contact with an antibody specific to ganglioside GM2 and/or an antibody specific to ganglioside GD1a, to obtain an antigen-antibody complex, and (2) detecting the antigen-antibody complex; and a pharmaceutical composition for treating pancreatic cancer, comprising a GM2 immune complex wherein an anticancer drug or a photosensitizer is bound to an antibody specific to ganglioside GM2, and/or a GD1a immune complex wherein an anticancer drug or a photosensitizer is bound to an antibody specific to ganglioside GD1a.

Abstract: A zirconia material manufacturing method includes: dispersing hydroxyapatite powder in water to prepare a slurry having a hydroxyapatite powder concentration of 1%; and dipping zirconia in the slurry to form, on the zirconia, a coating layer containing hydroxyapatite.

Abstract: The purpose of the present invention is to provide an effective therapeutic pharmaceutical composition for treating pancreatic cancer. The problem can be solved by a pharmaceutical composition comprising a fibroblast growth factor receptor 4 inhibitor and a senolytic drug as active ingredients.

Abstract: The invention provides a gold-supporting catalyst comprising gold nanoparticles and a carrier consisting of porous ceramic obtained by firing a mixture comprising an aluminum compound, a lime component, and a plastic clay containing 1% by mass or less of feldspars and quartz, wherein the gold nanoparticles are supported in an amount of 0.01 to 10 parts by mass on the carrier based on 100 parts by mass of the carrier.

Abstract: A heat-resistant alloy contains Y, a content of Ni is a content of Ni is 58.0 mass % or greater, a content of Cr is 20.0 mass % or greater and 23.0 mass % or less, a content of Mo is 8.0 mass % or greater and 10.0 mass % or less, a content of Nb is 3.15 mass % or greater and 4.15 mass % or less, a content of O is 0.002 mass % or greater and 0.1 mass % or less, and a ratio of a content of Y in terms of mass to a content of O in terms of mass is 0.5 or greater and 100 or less.

Abstract: The present invention provides a disease model animal for tauopathies which reproduces the expression pattern of tau protein isoforms of adult human brain, that is, approximately equal amounts of 3R type tau and 4R type tau being expressed in the adult brain. The method for producing the disease model animal for tauopathies of the present invention comprises the steps of: preparing a tau seeds; and injecting the tau seeds in the brain of an animal carrying a mutation in the tau gene which fails to express the tenth exon. The animal carrying a mutation in the tau gene which fails to express the tenth exon may be produced by using any of the genome editing, gene targeting or base editing technologies.

Abstract: A heat-resistant alloy contains at least one element selected from a group consisting of Al, Ti, Ni, Cr, and Mo, O, and Y, and a ratio of a content of Y in terms of mass to a content of O in terms of mass is 0.5 or greater and 100 or less.

Abstract: The object of the present invention is to provide a therapeutic agent for treating hormone therapy-resistant, treatment-resistant cancers, and a method of the treatment of hormone therapy-resistant, treatment-resistant cancers. The problem can be solved by a pharmaceutical composition including a compound represented by the formula (1) or a salt thereof or a compound represented by the formula (2) or (3) or a salt thereof, as an active ingredient for treating prostate cancer. Furthermore, the pharmaceutical composition of the present invention can effectively treat not only hormone therapy-resistant prostate cancer or breast cancer but also non-hormone therapy-resistant prostate cancer or breast cancer and Castration-resistant prostate cancer or treatment-resistant breast cancer caused by other mechanisms.

Abstract: [Problem] The purpose of the present invention is to provide a deodorizing catalyst that can decompose a malodorous substance even at a low temperature of 100° C. or less. [Solution] A deodorizing catalyst for decomposing a malodorous substance, comprising: manganese oxide wherein the manganese oxide satisfies the following expression (1) and the following expression (2), and the manganese oxide has a maximum intensity peak at a diffraction angle (2?) of 37±1° in an X-ray diffraction pattern: 0<A?0.90 . . . ??(1) 0<B?250 . . .

Abstract: An additive manufacturing method is provided for building a manufacturing object by building of repeating formation of one of a sintered portion or a fused portion by selectively heating a thinly developed powder material within a working region on the basis of drawing data derived from three-dimensional data of the manufacturing object and further formation of a new thin layer on one of the sintered portion or the fused portion. The additive manufacturing apparatus includes one or more channels connecting the inside and the outside of the region, and introduces a fluid into a crack progressing into the un-fused powder material through the channel after completion of building to forcibly cool one of the sintered portion or the fused portion, and the un-fused powder material.

Abstract: The present invention provides a recombinant vaccinia virus serving as a clinically usable preventive vaccine for COVID-19 (vaccine for SARS-CoV-2), etc. The recombinant vaccinia virus of the present invention is characterized by comprising the whole or part of cDNA encoding nonstructural proteins or structural protein derived from SARS-CoV-2, and an expression promoter.

Abstract: The present invention relates to a highly oriented collagen fibril bundle having a length in a major axis direction of 1 m or more.

Abstract: The present invention aims to provide a peptide of the C region of HGS and an antitumor agent comprising the same having a higher tumor growth inhibitory effect as compared with conventional techniques. An antitumor agent comprising a peptide comprising at least 10 consecutive amino acid residues of the amino acid sequence of the C region of HGS is described.

Abstract: Provided are: a recombinant vaccinia virus which is effective for the prevention of the development of a disease by the infection by H7 avian influenza virus and has high safety; and a vaccine against H7 avian influenza virus, which comprises the recombinant vaccinia virus. The recombinant vaccinia virus according to the present invention is a recombinant vaccinia virus having such a structure that an expression promoter and the full length or a part of cDNA encoding hemagglutinin protein of H7 avian influenza virus are contained in the genome for vaccinia virus strain DIs.